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Objective: To investigate the in vitro interference of cefotaxime at subinhibitory con-
centrations [sub-minimal inhibitory concentrations (MIC)] on bioﬁlm formation by
nontypeable Haemophilus inﬂuenzae (NTHi).
Methods: The interference of subinhibitory concentrations of cefotaxime on bioﬁlm
formation of the clinical strong-bioﬁlm forming isolates of NTHi was evaluated by a
microtiter plate bioﬁlm formation assay. The effect of sub-MIC cefotaxime on bacterial
cell-surface hydrophobicity was determined using a standard microbial adhesion to
n-hexadecane test. Additionally, the effects on bacterial adherence to human ﬁbronectin
and expression of bacterial adhesins were also investigated.
Results: Subinhibitory concentrations of cefotaxime, both at 0.1× and 0.5× MIC levels,
efﬁciently reduced the NTHi bioﬁlm formation, and this effect was independent of
decreasing bacterial viability. Sub-MIC cefotaxime also decreased bacterial cell-surface
hydrophobicity and reduced adherence to human ﬁbronectin. Inhibition in the P2 and
P6 gene expressions upon exposure to sub-MIC cefotaxime was also noted.
Conclusions: Taken together, our results indicate that sub-MIC cefotaxime interferes
with the formation of NTHi bioﬁlm, and this effect is feasibly related to the interference
with cell-surface hydrophobicity, ﬁbronectin-binding activity as well as alteration of the
P2 and P6 gene expression. The ﬁndings of the present study therefore provide a rationale
for the use of subinhibitory concentrations of cefotaxime for treatment of NTHi-related
diseases.1. Introduction
Nontypeable Haemophilus inﬂuenzae (NTHi) is present as a
commensal and opportunistic pathogen that is highly adapted to
colonize the human respiratory tract and later progress to cause
mucosal infections in children and adults [1–3]. Thismicroorganism is responsible for an array of respiratory
diseases, including otitis media, sinusitis, conjunctivitis,
exacerbations of chronic obstructive pulmonary disease,
persistent bacterial bronchitis and cystic ﬁbrosis [2–4].
Signiﬁcant levels of morbidity and mortality as well as
socioeconomic burden caused by this microorganism have
been of great concern worldwide. Several lines of evidence
revealed the presence of NTHi in bioﬁlm communities in the
lower and upper airways, and physically in the middle-ear mu-
cosa of experimental chinchilla models of otitis media [5,6].
Bacterial pathogens living in bioﬁlm are resistant to
antimicrobials and host immune clearance [5]. Compared with
the planktonic ones, bacteria within the bioﬁlm state have
been shown to be more than 1000-times more resistant to
conventional antibiotic treatment and host immune responses [7].
As such, bacterial bioﬁlms are difﬁcult to eradicate, and oftenarticle under the CC BY-NC-ND license (http://
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difﬁcult-to-eradicate infection associated with bioﬁlm represents
a major challenge in medical practice on a global scale.
Generally, effective antimicrobial treatment is expected when
the antibiotic concentration is above the minimal inhibitory
concentration (MIC). However, after a certain period of time
following a dose, antibiotic concentrations become lower than
the conventionally determined MIC and this often occurs at the
site of infections [11]. The subinhibitory concentrations (sub-
MICs) of antibiotics, although not able to kill microorganisms,
have been shown to alter the chemical and physical cell-
surface characteristics and consequently the functionality and
expression of bacterial virulence parameters such as adherence,
cell-surface hydrophobicity (CSH), bioﬁlm formation and
motility [12,13]. These evidences strongly indicate the
effectiveness of antibiotics at sub-MIC levels and suggest their
possible beneﬁts to new treatments for microbial infections, in
particular those that are associated with bioﬁlm [14]. For NTHi,
while vaccine development is a key direction to prevent the
infections, this strategy is promisingly in progress. To date,
most therapeutic guidelines for NTHi treatment rely only on
the existing antibiotics. Considering this, application of such
alternative actions of antibiotics where signiﬁcant virulence
properties are altered would be valuable, providing a potential
approach to control the infections caused by NTHi bioﬁlm.
This study therefore investigated the in vitro interference of
cefotaxime at subinhibitory concentrations on bioﬁlm formation
of NTHi. In addition, the effects of sub-MIC cefotaxime against
a number of virulence properties expressed by clinical NTHi
isolates were also evaluated.
2. Materials and methods
2.1. Bacterial strains and culture conditions
NTHi strains NU11 and NU47 used in this study were
originally isolated from the respiratory clinical specimens
(sputum and pus) from patients hospitalized at Buddhachinaraj
Hospital (Phitsanulok, Thailand). The bacteria were identiﬁed
according to standard microbiological procedures and PCR-
serotyped as described previously [15]. All isolates were
reconstituted from frozen glycerol stocks and propagated on
brain heart infusion (BHI; Oxoid, Basingstoke, England) agar
or broth supplemented with nicotinamide adenine dinucleotide
(Becton Dickinson, Maryland, USA; 10 mg/mL) and hemin
(Becton Dickinson; 10 mg/mL) at 37 C under 5% CO2.
2.2. MIC and minimum bactericidal concentration
(MBC) determination
MIC was determined by a broth microdilution method ac-
cording to guidelines from the Clinical and Laboratory Stan-
dards Institute [16] using Haemophilus test medium (HTM).
Two-fold serial dilutions of cefotaxime (Sigma–Aldrich, St
Louis, MO, USA) were prepared in HTM in 96-well microtiter
plates (Nunc™, Roskilde, Denmark). An adjusted bacterial
inoculum was then added to each well to achieve a ﬁnal con-
centration of 5 × 105 CFU/mL. The ﬁnal concentration of
cefotaxime ranged from 0.25 to 512 mg/mL. The MIC was
deﬁned as the lowest antibiotic concentration that yielded no
visible growth after incubation at 37 C in a 5% CO2 atmospherefor 24 h. To determine MBC, 10 mL was aspirated from the
wells where there was no visible growth in the MIC experiment
and plated onto BHI agar. The plates were incubated at 37 C
under 5% CO2 for 24 h and the MBC was deﬁned as the lowest
antibiotic concentration at which more than 99% of bacteria
were killed compared with a non-treated control.
2.3. Bioﬁlm formation assay
The ability of NTHi to form bioﬁlm was determined based on
a method described previously [17] with some modiﬁcations.
Overnight cultures of NTHi were washed, diluted 1:200 in
fresh HTM and aliquots (200 mL) of the inoculum were added
into the wells of 96-well ﬂat-bottom microtiter plates (Nunc™,
Roskilde, Denmark). Plates were incubated at 37 C under 5%
CO2 for 18 h without agitation. Prior to bioﬁlm quantitation,
growth was assessed by measuring the optical density (OD) at
600 nm using a microplate reader (Labsystem iEM Reader MF).
Bioﬁlms were then quantitated by staining the adherent cells
with 1% (w/v) crystal violet solution for 15 min, after which the
stained bioﬁlms were washed with deionized water to remove
unbound dye. The crystal violet bound to the bioﬁlms was
solubilized in 200 mL of 95% ethanol and the OD was deter-
mined at 540 nm. Bioﬁlm forming index (BFI) was used to
express the amounts of bioﬁlm formed by NTHi. This was
calculated using the formula (AB − CW)/G, in which AB is the
OD of the stained attached microorganisms, CW is the OD of
the stained control wells containing microorganisms-free me-
dium only and G is the OD of the cells growth in suspended
culture. Semi-quantitative classiﬁcation of bioﬁlm formation
designated as strong, moderate, weak or none was interpreted
from the BFI readings [18]. All NTHi strains were tested in
quadruplicate for each experiment, and the results were
reported as two independent experiments.
2.4. Sub-MIC effect of cefotaxime on bioﬁlm formation
Effect of sub-MICs of cefotaxime on NTHi bioﬁlm formation
was examined by a microdilution method. Overnight cultures of
NTHi adjusted to a ﬁnal concentration of 5 × 105 CFU/mL were
inoculated into the wells of 96-well ﬂat-bottom microtiter plates
(Nunc™) and the plates were incubated at 37 C under 5% CO2
for 4 h. The medium was discarded and bioﬁlms were then
exposed to cefotaxime (Sigma–Aldrich) at the concentrations of
0.1× and 0.5× MICs. Following incubation at 37 C in a 5%
CO2 atmosphere for 18 h, the medium and unattached cells were
decanted and the wells were washed thoroughly with sterile
deionized water. Bioﬁlms were quantitated by the bioﬁlm for-
mation assay as described in Section 2.3. Non-treated control
consisted of bacteria that were not exposed to the test antibiotic
but otherwise treated identically. The percentage of bioﬁlm
formed in the presence of different concentrations of the test
antibiotic was calculated using equation (OD540 of the test/
OD540 of non-treated control) × 100.
2.5. Determination of cell viability at sub-MIC of
cefotaxime
The effect of cefotaxime at sub-MIC level on viability of
NTHi was determined in 125 mL ﬂasks containing 25 mL of a
bacterial culture (5 × 105 CFU/mL, ﬁnal concentration) and
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run without the test antibiotic but containing bacterial inoc-
ulum at equal cell density. The cultures were grown at 37 C
under 5% CO2. At 0, 4, 8, 12 and 16 h, samples were taken
and viable counts were determined as follows: the samples
were serially diluted in sterile phosphate buffer pH 7.2 and
100 mL aliquots were plated onto BHI agar. The plates were
incubated at 37 C under 5% CO2 for 24 h, followed by
enumeration of the CFU.
2.6. CSH assay
The CSH of the bacterial cells treated with 0.1× and 0.5×
MIC cefotaxime as well as untreated cells was carried out using
a standard microbial adhesion to n-hexadecane test [19]. Brieﬂy,
4 mL of bacterial suspension prepared in 0.9% NaCl at an OD550
of 0.8 was overlaid with 400 mL n-hexadecane (Sigma–Aldrich).
After 1-min agitation, the phases were allowed to separate for
15 min at room temperature. The OD of the aqueous phase was
measured at 550 nm. The results were expressed as the pro-
portion of cells that were excluded from the aqueous phase,
determined by the equation: {[OD550 (original bacterial
suspension) − OD550 (aqueous phase)]/OD550 (original bacterial
suspension)} × 100.
2.7. Fibronectin-binding assay
Fibronectin-binding assay was performed using human
ﬁbronectin coated 96-well microtiter plates (R&D Systems,
Minneapolis, USA). Before the assay, NTHi strains were
exposed to 0.1× and 0.5× MIC cefotaxime for 18 h at 37 C in
a 5% CO2 atmosphere. The bacteria adjusted to a ﬁnal con-
centration of 5 × 105 CFU/mL were then added to the
ﬁbronectin-coated wells and the plates were incubated at 37 C
under 5% CO2 for 18 h. After washing with sterile deionized
water, bound cells were stained with 1% (w/v) crystal violet
for 15 min at room temperature. Plates were washed again
with sterile deionized water and allowed to air dry. The dye
incorporated by the adherent cells was solubilized in 200 mL
of 95% ethanol and the OD measured at 540 nm. The OD
value obtained from each strain without the test antibiotic was
used as the control.
2.8. RNA extraction
Bioﬁlms grown in the presence of 0.5× MIC cefotaxime were
undertaken as above. Bioﬁlm cells were harvested and centri-
fuged at 3500 r/min for 10 min. The bacterial pellet was sus-
pended in Trizol reagent (Invitrogen™, USA) and RNA
extraction was performed as per manufacturer protocol. RNA
concentration and purity was determined by measuringTable 1
Primers used in PCR ampliﬁcations.
Target gene Primer name Sequence (50 to 30)
ompP2 P2-F ACGCGGATCCTGCTGTTGTTTATAACA
P2-R ATCAGGATCCTTAGAAGTAAACGCGT
ompP6 P6-F TTGGCGGWTACTCTGTTGCT
P6-R TGCAGGTTTTTCTTCACCGT
16S rRNA 16S rRNA-F TCCTAAGAAGAGCTCAGAGAT
16S rRNA-R TGATCCAACCGCAGGTTCCabsorbance at both 260 and 280 nm on a NanoDrop spectro-
photometer (NanoDrop Technologies, USA).
2.9. RT-PCR assay
Gene expression was determined by RT-PCR assay. cDNA
was obtained using RevertAid™ H Minus ﬁrst strand cDNA
synthesis kit (Fermentas) following the manufacturer's in-
structions. cDNA was synthesized in 20 mL reaction mixture
using 0.5 mg/mL oligo (dT) and 5 mg extracted RNA as template.
A negative control containing the reaction components without
reverse transcriptase was included to ensure no DNA
contamination.
The PCR ampliﬁcation was carried out using the synthe-
sized cDNA as template. Gene speciﬁc primers used in this
study are listed in Table 1. The 25 mL reactions consisted of
1× DreamTaq™ Green PCR Master Mix (Fermentas, Can-
ada), 1 mmol/L each forward primer and reverse primer and
2 mL of cDNA. Ampliﬁcations were performed in a Gene Q
Thermal Cycler (Bioer Technology, China). The PCR con-
ditions consisted of an initial denaturation step of 94 C for
3 min, followed by 35 cycles of denaturation at 94 C for
1 min, annealing at 55 C for 1 min (for P2) or 30 cycles of
denaturation at 94 C for 30 s, annealing at 58 C for 30 s,
extension at 72 C for 1 min (for P6 and 16S rRNA), and
ﬁnal extension step of 10 min at 72 C. The PCR products
were electrophoresed through a 1% agarose gel and visual-
ized with an ultraviolet transilluminator after ethidium bro-
mide staining. The band intensity was determined by ImageJ
software. The intensities of the PCR products of the P2 and
P6 gene were expressed as ratios to the 16S rRNA control
gene. The ratios were then compared between the control
(without the test antibiotic) and the test exposed to 0.5× MIC
cefotaxime.2.10. Statistical analysis
Data are expressed as mean ± SEM. All data were statisti-
cally analyzed by Student's t-test using SPSS version 11.5
(SPSS, Chicago, IL, USA). The differences were considered
statistically signiﬁcant for P < 0.05.3. Results
3.1. MIC and MBC
The MICs of cefotaxime were 48 and 64 mg/mL while the
MBCs were 160 and 320 mg/mL for NTHi strains NU11 and
NU47, respectively. It is noted that the MBC values were 3–5
times higher than their corresponding MIC values.Temperature (C) Amplicon size (bp) References
ACG 67.4 1113 [20]
AAACCTAC 67.1
56.7 296 [21]
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Figure 2. Effects of sub-MIC of cefotaxime on viability of NTHi.
The bacteria (NU11, NU47) were grown in HTM with 0.5× MIC cefo-
taxime at 37 C, 5% CO2. A culture without the test antibiotic was used as a
control. Viable cell counts were assessed at the indicated time points.
Values are the means of two experiments.
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The ability of clinical NTHi isolates NU11 and NU47 to
form bioﬁlm was determined on the static condition and
expressed as BFI. The BFI values of NU11 and NU47 were
1.41 ± 1.17 (bioﬁlm OD, 0.463; growth OD, 0.328) and
3.08 ± 1.29 (bioﬁlm OD, 1.917; growth OD, 0.622), respec-
tively. According to the semi-quantitative classiﬁcation of
bioﬁlm formation, any bacteria with BFI values  1.10 are
deﬁned as strong-bioﬁlm producers [18]. The results indicated
that the clinical NTHi isolates in this study were capable of
forming bioﬁlms and that all were strong-bioﬁlm producing
strains.
3.3. Effect of sub-MICs of cefotaxime on NTHi bioﬁlm
formation
The effect of sub-MIC cefotaxime on bioﬁlm formation of
the clinical NTHi strains NU11 and NU47 is shown in
Figure 1. Modiﬁcation on bioﬁlm formation was obviously
observed upon the addition of sub-MIC cefotaxime. The
amounts of bioﬁlm formation for NU11 and NU47 signiﬁcantly
lowered (P < 0.01) in the presence of 0.1× MIC of cefotaxime
than that of the non-treated control (without the test antibiotic),
with the inhibition levels of 44.78% and 57.73%, respectively.
The bioﬁlm reduction level of up to 80% (NU11) was signif-
icantly (P < 0.01) detected when exposed to 0.5× MIC of
cefotaxime. It was also noted that, although varying in degrees,
the inhibitory effects were observed in both of the clinical
NTHi strains studied.100
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Figure 1. Effect of sub-MICs of cefotaxime on bioﬁlm formation of NTHi
strains NU11 and NU47.
Culture without the test antibiotic was used as the non-treated control.
Results are expressed as the percentage of the non-treated control formed
bioﬁlm. Data represent the mean ± SEM of three observations. **: P < 0.01
compared to the control.
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Figure 3. Effect of sub-MICs of cefotaxime on cell surface hydrophobicity
of NTHi strains NU11 and NU47.
The control contained bacteria that were not exposed to cefotaxime. Data
represent the mean ± SEM of two independent experiments.3.4. Effect of sub-MIC cefotaxime on cell viability
As shown in Figure 2, all studied NTHi cultures, although
slightly delayed in growth rate, continued to grow after
addition of 0.5× MIC cefotaxime and the total bacterial counts
appeared to be similar to those of the non-treated control
cultures after prolonged exposure to the test antibiotic. The
results suggested that cefotaxime at sub-MIC levels has no
bactericidal.3.5. Effect of sub-MICs of cefotaxime on CSH
The effect of sub-MICs of cefotaxime on CSH was assessed
based on the bacterial adherence to hydrocarbon n-hexadecane.
As shown in Figure 3, CSH in the test strains was affected in
varying capacity when treated with sub-MICs of cefotaxime.
Decrease in CSH of the test strains, in comparison to the non-
treated control, was obviously demonstrated when exposed to
0.5× MIC cefotaxime. The reduction levels appeared to be
80.51% and 50.68% for NU11 and NU47, respectively.3.6. Effect of sub-MICs of cefotaxime on ﬁbronectin-
binding activity
The ability of NTHi after the exposure to sub-MICs of
cefotaxime to bind to host extracellular matrix ﬁbronectin was
investigated using a microtiter plate adherence assay. As shown
in Figure 4, the ﬁbronectin-binding activity of NTHi strains
NU11 and NU47 was signiﬁcantly reduced (P < 0.01) after the
exposure to 0.1× MIC of cefotaxime as compared with that of
non-treated control. The reduction levels for NU11 and NU47
were 56.75% and 46.43%, respectively. Signiﬁcant decrease in
ﬁbronectin-binding activity was also observed when the test
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reduction levels of 60.58% and 44.92% for NU11 and NU47,
respectively.120
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Figure 4. Effect of sub-MICs of cefotaxime on NTHi strains NU11 and
NU47 binding to human ﬁbronectin.
The control contained bacteria that were not exposed to cefotaxime. Data
represent the mean ± SEM of two independent experiments. *: P < 0.05, **:
P < 0.01 compared to the control.3.7. Effect of sub-MICs of cefotaxime on expression of
P2 and P6 genes
To further investigate whether sub-MIC cefotaxime altered
the expression of NTHi adhesin genes, semi-quantitative RT-
PCR was performed. Figure 5 shows that in the absence of the
test antibiotic the NTHi strains in this study, although differed in
degrees, expressed both the P2 and P6 genes. Expression of the
P2 gene in relation to 16S rRNA was inhibited after the NTHi
culture was exposed to 0.5× MIC cefotaxime (Figure 5A),
compared to the culture without the test antibiotic. Signiﬁcant
down-regulation (P < 0.01) was also detected for the P6 gene
after the exposure to 0.5× MIC of cefotaxime, compared to non-
treated control (Figure 5B).1.2
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Figure 5. The relative mRNA levels of the adhesion P2 (A) and P6 (B)
genes to 16S rRNA gene after exposure to 0.5× MIC of cefotaxime.
The values are the mean ± SEM of two sets of results. **: P < 0.01
compared to the control.4. Discussion
This study reports the in vitro interference of cefotaxime at
subinhibitory concentrations on bioﬁlm formation of NTHi. The
results herein demonstrated that subinhibitory concentrations of
cefotaxime efﬁciently decreased the formation of NTHi bioﬁlms.
This bioﬁlm inhibitory activity was evidenced both at 0.1× and
0.5× MIC levels and in all the NTHi strains studied. The NTHi
used in this study were isolated from clinical specimens and were
all veriﬁed to be strong bioﬁlm producers. Our results therefore
suggested that the bioﬁlm inhibitory activity of sub-MIC cefo-
taxime occurred among various strong bioﬁlm-forming clinical
isolates of NTHi, even with the very strong bioﬁlm-producing
strain (NU47). These ﬁndings indicate the potent bioﬁlm inhibi-
tory activity of sub-MIC cefotaxime and suggest its potential use
for treatment of bioﬁlm-related NTHi infections.
The bioﬁlm inhibitory activity in this study was observed after
the addition of sub-MIC cefotaxime to the initial NTHi bioﬁlms
(4 h), and that bioﬁlm inhibition is independent of decreasing
bacterial viability, it is possible that sub-MIC cefotaxime
inhibited NTHi bioﬁlm formation by interfering the early step of
bacterial adhesion. The initial adherence and colonization to
surfaces is the ﬁrst crucial step for establishment of infection and
the following bioﬁlm formation. Our ﬁndings are thus of clinical
importance because cefotaxime at sub-MIC levels may act as an
anti-adherent and anti-bioﬁlm agent, and its presence would
prevent establishment of infection and subsequently inhibit the
bioﬁlm formation. Interfering the requisite virulence properties
(e.g. bacterial adherence) directly, rather than the vital cellular
growth or viability provides an attractive alternative for limiting
or reducing the severity of infections [23]. Since anti-bioﬁlm ac-
tivity does not affect the vital bacterial viability, cefotaxime at
sub-MIC levels will possibly exert limited selective pressure on
NTHi and therefore may avoid development of resistant bacteria.
Enormous literature so far has provided evidence that a number
of pathogenic bacteria depend on the hydrophobic interactions for
successful adherence to and colonization on host cells [24,25]. A
positive correlation between hydrophobicity and both levels of
bacterial adhesiveness and bioﬁlm formation has been described
[25–27], thus emphasizing signiﬁcance of hydrophobicity for
bacterial infections. In this study, decreased cell-surface hydro-
phobicity was obviously seen after the test NTHi were exposed to
sub-MIC cefotaxime. Consistently, signiﬁcant reduction on the
ability to bind to ﬁbronectin was also observed after treated the
NTHi strains with cefotaxime at sub-MIC levels. Fibronectin is an
extracellular matrix protein of host cells, and interactions with
extracellular matrix ﬁbronectin have been reported to be one of the
successful adherence strategies employed byNTHi [28]. Our results
indicated the effectiveness of sub-MIC cefotaxime in reducing the
critical step in bacterial adherence to host cells. Thus, these ﬁnd-
ings further strengthened the potential use of sub-MIC cefotaxime
for interrupting the establishment of infection and the subsequent
stage of NTHi bioﬁlm development.
In order to provide additional insight into the mechanisms by
which sub-MIC cefotaxime decreased bacterial adherence and
inhibited bioﬁlm formation, alteration in gene expression of
bacterial components conferring cell-surface interaction as well
as bioﬁlm development was determined. The outer membrane
proteins P2 and P6 are Haemophilus inﬂuenzae surface struc-
tures that play a signiﬁcant role in the initial binding of bacteria
to host cells [29]. Previous studies also revealed that these two
proteins are expressed during growth as a bioﬁlm [17].
Sudarat Baothong et al./Asian Pac J Trop Biomed 2016; 6(9): 745–750750Recently, bioﬁlm-speciﬁc proteins presented in immature bio-
ﬁlms were investigated, and the outer membrane protein P2 was
one of the two proteins identiﬁed [30]. The fact that inhibition in
both P2 and P6 gene expressions upon the exposure to sub-MIC
cefotaxime was noted in this study, cefotaxime at sub-MIC
levels might interrupt the expression of P2 and P6 genes,
thereby reducing expression of NTHi adhesins, and subse-
quently leading to the decreased bacterial adherence and the
inhibition NTHi bioﬁlm formation.
In conclusion, the present study demonstrated for the ﬁrst
time that cefotaxime at subinhibitory concentrations inhibited
bioﬁlm formation of the clinical strong-bioﬁlm forming NTHi
isolates. Such anti-bioﬁlm effects were possibly related to
interference with cell-surface hydrophobicity, ﬁbronectin-
binding activity as well as alteration of the P2 and P6 gene
expression. Since other bacterial adhesins or other nonadhesin
components or even other mechanisms by which sub-MIC
cefotaxime interfered with NTHi bioﬁlm development may be
involved and should not be excluded, further studies remain to
be investigated. Nevertheless, our data provide a rationale for the
use of subinhibitory concentrations of cefotaxime in diseases
involving NTHi bioﬁlms. Future work is required to conﬁrm our
ﬁndings in vivo with an appropriate animal model.Conﬂict of interest statement
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